Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias
Portfolio Pulse from
Kura Oncology and Kyowa Kirin have entered a global strategic collaboration to develop and commercialize Ziftomenib for acute leukemias. Kura will receive a $330 million upfront payment and up to $1.2 billion in milestone payments.
November 20, 2024 | 10:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Kyowa Kirin collaborates with Kura Oncology to develop Ziftomenib, involving a $330 million upfront payment and potential milestone payments up to $1.2 billion.
Kyowa Kirin's collaboration with Kura Oncology to develop Ziftomenib could enhance its product portfolio and market presence, potentially benefiting its stock price.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 80
POSITIVE IMPACT
Kura Oncology has partnered with Kyowa Kirin to develop Ziftomenib, receiving a $330 million upfront payment and potential milestone payments up to $1.2 billion.
The partnership with Kyowa Kirin provides Kura Oncology with significant financial resources, including a $330 million upfront payment and potential milestone payments, which could positively impact its stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100